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Abstract
Background: Asherman’s syndrome (AS) is a rare reproductive abnormality, resulting
in endometrial collapse due to aggressive or recurrent endometritis and/or curettage.
Objective: We aimed to assess the effectiveness of using platelet-rich plasma (PRP) to
lower the recurrence rate of intrauterine adhesions (IUAs) following hysteroscopy.
Materials and Methods: In this non-randomized clinical trial, women aged 20-
45 yr with AS diagnosed by sonohysterography, 3D sonography, hysteroscopy,
or uterosalpingography between May 2018 and September 2018 were included.
Participants (n = 30) were divided into case and control groups. Following hysteroscopic
adhesiolysis, a Foley catheter was placed into the uterine cavity in all women. After two
days, the catheter was removed, and 1-mL PRP was injected into the uterine cavity
of women in the PRP (case) group, while the control received no PRP. All controls
and subjects underwent diagnostic hysteroscopy 8-10 wk following the intervention to
assess the IUAs according to the American Society for Reproductive Medicine scoring
system.
Results: Our results did not reveal any significant difference in the menstrual pattern
of either the control or test groups before or after treatment (p = 0.2). Moreover, the
IUA stage in both studied groups before and after treatment was similar (p = 0.2). The
duration of menstrual bleeding in both studied groups before and after treatment was
also similar.
Conclusion: PRP cannot change the menstrual pattern or development of postsurgical
AS, as evaluated by follow-up hysteroscopy.
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1. Introduction
As a unique tissue in adult humans, the uterine
endometrium bears the potential to sustain
some changes such as shedding physiologically
at certain intervals followed by regeneration
at virtually monthly periods unless a female’s
reproductive system fails to function properly.
cooperation of some tissues including endothelial,
epithelial, and progenitor cells as well as
fibroblasts and their reaction to local signaling
from tissue microenvironment assists in successful
implementation of this critical repairing process
of tissues. The process subsumes proliferation
of the cells, their migration, accompanied by
lineage differentiation, and transdifferentiation via
mesenchymal-to-epithelial transition. However,
if this tightly regulated homeostatic balance is
disturbed, the consequences are endometrial
pathologies, poor pregnancy outcomes, and
infertility (1).
One of the unusual gynecological disorders
induced by the destruction of the endometrium
and emerges from frequent or aggressive
curettage and/or endometritis is Asherman’s
syndrome (AS) (2). Consequently, in many areas,
a loss of functional endometrium occurs and is
accompanied by obliteration of the uterine cavity,
which results from intrauterine adhesions (IUAs)
and induces infertility, recurrent pregnancy loss,
hypomenorrhea, amenorrhea, placenta previa, and
placenta accrete (3).
Management and therapeutic strategies involve
hysteroscopic adhesiolysis and re-adhesion
prevention using intrauterine devices, Foley’s
catheter, uterine balloon stent, or amnion grafts
(4).
In order to help generate a healthy layer of
the cells and hence support pregnancy, the AS
management should, therefore, be oriented toward
eliminating any adhesion and controlling their
regeneration.
To restore endometrial function, some
therapeutic attempts have been made including
the application of exogenous estrogen, vaginal
sildenafil citrate, aspirin, pentoxifylline and vitamin
E; yet the outcomes need to be improved (4).
Comprising serum with a platelet concentration
greater than 10 × 105 platelets per cubic microliter,
platelet-rich plasma (PRP) is a rich source of growth
factors that has antigenic and mitogenic features
and includes platelet-derived growth factor,
epidermal growth factor, fibroblast growth factor,
transforming growth factor-beta, and vascular
endothelial growth factor (5).
The role these growth factors in modulating
endometrial cell proliferation and differentiation
has been identified. Several investigations to date
have assessed the role of intrauterine instillation of
autologous PRP in suboptimal endometrium, that
is, to improve embryo transfer (ET) and vascularity
(6-8). Hence, PRP is expected to exert beneficial
effects on damaged endometrium. In addition,
based on long-term clinical experience, the use of
PRP is considered safe, and unlike bone marrow-
derived stem cells (BMDSCs), it can be much more
readily obtained (9).
The present study aimed to evaluate the impact
of PRP use in reducing the recurrence of IUAs
following their lysis by hysteroscopy.
2. Materials and Methods
In this non-randomized clinical trial, 30
women aged 20 to 45 yr with AS diagnosed
based on 3D sonography, sonohysterography,
hysterosalpingography, or hysteroscopy from
May 2018 to September 2018 were included. The
women were referred to the Research and Clinical
Center for Infertility, Yazd, Iran and were divided
into two groups: case (PRP group) and control (n =
15/each) groups. Women who used anticoagulants
or NSAIDs within at least 10 days prior to the
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procedure, those with any major disorders that
might have compromised the ability of patients to
provide consent, and those with active cervical
or uterine infections were excluded. For those in
the case group, 1 ml of PRP was injected into the
uterine cavity, whereas for those in the control
group, no injection was given.
The demographic data, laboratory, and checkup
results prior to and after treatment were recorded.
The severity of IUA was appraised based on
hysteroscopic findings including amount of cavity
involved and type of adhesion as well as clinical
symptoms (menstrual status) according to the
American Society of Reproductive Medicine
(ASRM) scoring system (10). After hysteroscopic
adhesiolysis, for both groups, a Foley catheter was
inserted into the uterine cavity. Two days after
hysteroscopy, the Foley catheter was removed,
and 1 ml of PRP was injected into the uterine
cavity in women in the PRP group, but no PRP
injection was given to women in the control group.
To evaluate IUAs by the ASRM score, all cases
and controls underwent diagnostic hysteroscopy
for 8 to 10 wk following the intervention (Figure
1).
Menstrual bleeding duration in the case and
control groups was assessed by questionnaire.
PRP preparation method: In the PRP group,
on the 13th day of the menstrual cycle, 8.5 ml
of peripheral venous blood was taken through
a syringe containing 1.5 ml of acid citrate, as
well as an anticoagulant solution (ACD-A) (Arya
Mabna Tashkhis, Iran); it was then centrifuged
immediately at 1600 g for 10 min. Division of the
blood into three layers was performed: cellular
plasma situated over, red blood cells (RBCs) at the
bottom, and a buffy coat layer in between the two
other layers. The buffy coat and plasma layer were
both collected and transferred to another tube so
as to be centrifuged again at 3500 g for 5 min;
1.5 ml PRP at a 4-5 times higher concentration and
2000 lymphocytes were finally obtained.
Assessed for eligibility (n = 30)
Analyzed (n = 15) 
Lost to follow-up (6-8 wk) (n = 0)
Allocated to case group (n = 15)
PRP injected into uterine cavity
Lost to follow-up (6-8 wk) (n = 0)
Allocated to control group (n = 15)





Asherman’s Syndrome Randomized (n = 30)
Figure 1. Consort flow diagram of study.
2.1. Ethical consideration
Data collection and document review in
this study were in accordance with the Ethics
Committee of the Research and Clinical Center
for Infertility, Shahid Sadoughi University
of Medical Sciences, Yazd, Iran (Code:
IR.SSU.MEDICINE.REC.1396.256), and with
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the 1964 Declaration of Helsinki and its later
amendments or comparable ethical standards.
All study participants provided written informed
consent.
2.2. Statistical analysis
Data were analyzed using Statistical Package for
the Social Sciences 20.0 (SPSS, SPSS Inc, Chicago,
Illinois). Continuous data were presented as the
mean ± standard deviation and were assessed by
independent Student’s 𝑡 test. P-values < 0.05 were
considered statistically significant.
3. Results
The demographic characteristics of the
study patients were similar in both groups
(Table I). Our results did not reveal any
significant difference in the menstrual
pattern of women in both groups before
and after treatment (Table II). The IUA stage
of both groups before and after treatment
was similar (Table III), and the menstrual
bleeding duration of both groups before
and after treatment was also similar (Figure
2).
Table I. Demographic characteristics of the study patients in the two groups
Variable PRP group (n = 15) Control group (n = 15) P-value
Age (yr) 35.93 ± 8.61 36.53 ± 5.38 0.821*
Gravidity
Nulligravida 8 (53.33) 6 (40)
Multigravida 7 (46.66) 9 (60)
1.000**
Possible etiology of AS
Myomectomy 6 (40) 2 (13.33)
Surgical hysteroscopy 3 (20) 5 (33.33)
D & C 6 (40) 8 (53.33)
0.248**
Data are presented as the Mean ± Standard Deviation (SD) and number (%); *Student’s 𝑡 test; **Chi-squared test; PRP: Platelet-
rich plasma; AS: Asherman’s syndrome; D & C: Dilation and curettage
Table II. Menstrual pattern of both groups before and after treatment
Variable PRP group (n = 15) Control group (n = 15) p-value*
Before treatment
Amenorrhea 2 (13.33) 0
Hypomenorrhea 10 (66.66) 9 (60)




Hypomenorrhea 6 (40) 6 (40)
Normal menstrual bleeding 9 (60) 9 (60)
0.645
Data are presented as numbers (%); *Chi-squared test; PRP: Platelet-rich plasma
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Table III. Intrauterine adhesion stage of both groups before and after treatment
Variable PRP group (n = 15) Control group (n = 15) P-value*
Before treatment
Stage I 2 (13.33) 1 (6.66)
Stage II 2 (13.33) 4 (26.66)
Stage III 11 (73.33) 10 (66.66)
0.592
After treatment
Stage I 2 (13.33) 6 (40)
Stage II 10 (66.66) 6 (40)
Stage III 3 (20.01) 3 (20)
0.223
Data are presented as numbers (%); *Chi-squared test; PRP: Platelet-rich plasma; Stage I: Mild; Stage II: Moderate; Stage III:
Severe
Figure 2. Menstrual bleeding duration (days) of both groups before and after treatment.
4. Discussion
The objective of this study was to examine
the potential intrauterine employment of PRP
so as to improve processes that are associated
with endometrial regeneration needed for the
management of AS. However, we did not show
that the intrauterine injection of PRP improves
hysteroscopy outcomes after surgical removal of
IUAs. These findings fail to be in agreement
with those of a previous study conducted
on a small sample, which recognized that
the development of postoperative IUAs is
lowered by PRP, as evaluated by subsequent
hysteroscopy.
Studies have recently worked on murine
models and identified the potential of BMDSCs
in improving the regeneration of damaged
endometrium (11).
However, there is still controversy in terms of the
usability and safety of BMDSCs. Researchers tend
to know more about their immunogenic reactions
and their impact on endometrial proliferative
disorders, including infections, endometriosis, as
well as the invasive process of harvesting these
cells (12).
In Jichun Tan and coworker study that
performed on seven patients suffered from AS,
first, autologous menstrual blood-derived stromal
cells (MenSCs) were isolated and cultured from
the menstrual blood of women within ∼2 wk; they
were then transplanted back into women’s uterus.
Following cell therapy, endometrial growth and
pregnancy were appraised the results of which
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indicated a significant improvement in ET (13).
Yet, in another study, S. Zhang et al. employed
transplantation of MenSCs and treatment with PRP
to reveal the great capacity of MenSCs in cell-
based treatment of AS. Endometrial proliferation
and vascular numbers escalated following
transplantation; however, fibrosis hyperplasia
was improved. Moreover, PRP increased the
stemness properties of MenSCs and heightened
their effectiveness in vivo, and, specifically,
inhibition of inflammatory effect was revealed.
Accordingly, the promising capacity of PRP in
cell-based therapy for AS has been confirmed and
is being considered as potentially vital for clinical
application (14).
In women who underwent frozen ET cycles for
the first time, Chang et al. evaluated the role
of autologous PRP in the thin endometrium in
five patients and demonstrated an increase of
endometrial thickness at 48 to 72 h after PRP
infusion in all patients (>7 mm on the day of
progesterone administration) so that all of them
became pregnant (6).
In another study, we appraised the impact of PRP
in women with thin endometrium during a frozen-
thawed ET cycle. It was a randomized clinical trial in
which 83 women suffering from a poor endometrial
response to standard hormone replacement
therapy (HRT) were assessed. Whereas both
groups (control and case) received HRT, the PRP
group was infused by additional 0.5-1 cc of PRP into
the uterine cavity on the 13th day of the HRT cycle,
the result of which exhibited a significant increase
in the endometrial thickness in the PRP group;
in this group the implantation rate and per-cycle
clinical pregnancy rate were of significant rise as
well (15).
The first cases of intrauterine PRP infusion for AS
treatment were presented by L. Aghajanova. The
treatment was well tolerated, as it showed no short-
term or long-term complications, and seemingly
improved endometrial function, as demonstrated
by successful conception and ongoing clinical
pregnancies (16).
In a study of 60 patients with a history of primary
or secondary infertility with severe IUAs, who also
wished to conceive, Amer et al. evaluated the
effect of intrauterine injection of PRP following
hysteroscopy. Thirty patients (case group) were
injected with PRP and 30 others (control group)
with IU balloon, the results of which revealed a
significant increase in menses duration among
the PRP group after surgery (3.0 ± 1.2 days) and
an increase in preoperative menses duration (1.4
± 1.5 days) compared with the balloon group
after surgery (1.8 ± 1.3) and preoperative (1.3 ±
1.4) days (17). In that study, which differed from
ours, a higher volume of PRP was injected, and
the injection of PRP was performed immediately
after hysteroscopy; we, however, injected PRP
postoperatively with a 48-h delay.
In an experimental model of ethanol-induced
damage, Jang et al. demonstrated possible
recovery using autologous PRP treatment
to improve endometrial regeneration. They
concluded that intrauterine administration of
autologous PRP in a murine model of damaged
endometrium stimulates and accelerates the
regeneration of the endometrium and lowers
fibrosis (9).
Moreover, the evaluation of the effect of PRP
on different human endometrial cells involved in
tissue regeneration was performed by Lusine and
colleagues. They asserted that autologous PRP can
induce endometrial regeneration (18).
Because of our concern about dilution of a
low volume of PRP in the remaining fluid within
the uterus after hysteroscopy, we injected PRP
two days after hysteroscopy, whereas in most
other studies, PRP was injected immediately
after hysteroscopic surgery. It appears that
injection immediately after surgery leads to better
outcomes.
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In IUA surgery, the ultimate goal is to improve
pregnancy outcomes and not to restore a normal
uterine cavity or normal menstruation. In the
present study, no attempt was made to evaluate
the pregnancy rate following PRP application for
the treatment of IUAs with follow-up for pregnancy
outcomes.
5. Conclusion
Our findings showed that PRP cannot change
the menstrual pattern or the development of
postsurgical AS, as evaluated by follow-up
hysteroscopy.
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